- Home
- RNA vs MDGL Comparison
RNA vs MDGL Comparison
Compare RNA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | MDGL |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 10.0B |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RNA | MDGL |
|---|---|---|
| Price | $14.93 | $435.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 14 |
| Target Price | $69.26 | ★ $637.92 |
| AVG Volume (30 Days) | ★ 2.9M | 344.4K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $88.12 | $58.70 |
| Revenue Next Year | $18.11 | $46.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.06 | $265.00 |
| 52 Week High | $73.06 | $615.00 |
Technical Indicators
Market Signals| Indicator | RNA | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 4.22 | 39.32 |
| Support Level | $13.06 | $410.78 |
| Resistance Level | $72.52 | $452.22 |
| Average True Range (ATR) | 0.83 | 19.94 |
| MACD | -6.15 | 0.97 |
| Stochastic Oscillator | 3.11 | 23.73 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.